Jessica Menis (@jessicamenis) 's Twitter Profile
Jessica Menis

@jessicamenis

Medical Oncologist at University Hospital of Verona

ID: 838686418515988480

calendar_today06-03-2017 09:43:19

377 Tweet

295 Takipçi

168 Takip Edilen

Dr Eileen Parkes (@eileen_parkes) 's Twitter Profile Photo

A privilege to host Professor Tim Yap OxfordOncology today - world class presentation on novel DDRi strategies! Packed seminar and lots of inspired researchers

A privilege to host Professor Tim Yap <a href="/OxfordOncology/">OxfordOncology</a> today - world class presentation on novel DDRi strategies! Packed seminar and lots of inspired researchers
Misty Dawn Shields (@drshieldsmd) 's Twitter Profile Photo

🚨HUGE victory for SCLC!🚨 FDA Oncology, under Project Orbis and the FDA Center of Excellence, grants accelerated APPROVAL for tarlatamab (Imdelltra, DLL3 BiTE) Amgen Oncology for relapsed small cell lung cancer after platinum-based therapy! #LCSM SmallCellSMASHERS The Shields Lab

🚨HUGE victory for SCLC!🚨

<a href="/FDAOncology/">FDA Oncology</a>, under Project Orbis and the FDA Center of Excellence, grants accelerated APPROVAL for tarlatamab (Imdelltra, DLL3 BiTE) <a href="/AmgenOncology/">Amgen Oncology</a> for relapsed small cell lung cancer after platinum-based therapy! 

#LCSM <a href="/SclcSMASHERS/">SmallCellSMASHERS</a> <a href="/TheShieldsLab/">The Shields Lab</a>
Giannis Mountzios (@g_mountzios) 's Twitter Profile Photo

#ASCO24 A state of the art educational session on novel avenues in #EGFR mutant #NSCLC and EGFR/ALK targeting in early stage. Amazing talks by inspiring experts Stephanie Saw Jordi Remon and Xiuning Le MD PhD If you missed it, check it out on demand!!! #LCSM #some ASCO IASLC ESMO - Eur. Oncology

#ASCO24 A state of the art educational session on novel avenues in #EGFR mutant #NSCLC and EGFR/ALK targeting in early stage. Amazing talks by inspiring experts <a href="/stephanieplsaw/">Stephanie Saw</a> <a href="/JordiRemon/">Jordi Remon</a> and <a href="/LeXiuning/">Xiuning Le MD PhD</a> If you missed it, check it out on demand!!!
#LCSM #some <a href="/ASCO/">ASCO</a> <a href="/IASLC/">IASLC</a> <a href="/myESMO/">ESMO - Eur. Oncology</a>
Noemi Reguart (@nreguart) 's Twitter Profile Photo

Second practice changing trial of the day: ADRIATIC Durva consolidation vs plb after cCRT in LS-SCLC. Dual P. endpoints OS/PFS meet (3-y FUP): 24 mo OS gain (median 55.9 vs 33.4, HR 0.73) and 24% reduction in the risk of PFS/death (median 16.6 vs 9.2 mo, HR 0.76) #ASCO24 #LCSM

Second practice changing trial of the day: ADRIATIC Durva consolidation vs plb after cCRT in LS-SCLC. Dual P. endpoints OS/PFS meet (3-y FUP): 24 mo OS gain (median 55.9 vs 33.4, HR 0.73) and 24% reduction in the risk of PFS/death (median 16.6 vs 9.2 mo, HR 0.76) #ASCO24  #LCSM
Benjamin Besse (@benjaminbessemd) 's Twitter Profile Photo

Another promising B7H3 ADC in pts with Small Cell Lung Cancer. « SuperTopoi » payload. DAR=4. Very early data. No ILD. Unconfirmed ORR 61.3%. #ASCO24

Another promising B7H3 ADC in pts with Small Cell Lung Cancer. « SuperTopoi » payload. DAR=4. 
Very early data.
No ILD. 
Unconfirmed ORR 61.3%. 
#ASCO24
IASLC (@iaslc) 's Twitter Profile Photo

In this episode, host Alfredo Addeo MD leads a discussion on first-line treatment options for EGFR mutant #NSCLC, in Italian. W/guests Jessica Menis, from the University Hospital Trust of Verona, Italy, & Filippo De Marinis, from Istituto Europeo di Oncologia: bit.ly/EGFRoptionsIT #LCSM

In this episode, host <a href="/Alfdoc2/">Alfredo Addeo MD</a> leads a discussion on first-line treatment options for EGFR mutant #NSCLC, in Italian. W/guests <a href="/JessicaMenis/">Jessica Menis</a>, from the University Hospital Trust of Verona, Italy, &amp; <a href="/demarinisquadri/">Filippo De Marinis</a>, from Istituto Europeo di Oncologia: bit.ly/EGFRoptionsIT #LCSM
Noemi Reguart (@nreguart) 's Twitter Profile Photo

Honored to be part by of this exceptional group of KOL women in global oncology. Grateful to contribute to raising awareness and advancing lung cancer care